Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.66 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.66 |
| ▸ | PIM1 | P11309 | 1/20 | 0.66 |
| ▸ | PRKACA | P17612 | 1/20 | 0.66 |
| ▸ | LTK | P29376 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.66 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.66 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.66 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.66 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.66 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.66 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8920 | 0.80 | EGFR (1.00) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL29941271 | 0.80 | EGFR (1.00) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL8976752 | 0.79 | EGFR (0.78) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| Hydrochloric Acid SCHEMBL20856873 | 0.78 | EGFR (0.96) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| Hydrochloric Acid SCHEMBL29394578 | 0.78 | EGFR (0.96) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| Hydrochloric Acid SCHEMBL8808235 | 0.76 | EGFR (0.90) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL6823372 | 0.76 | EGFR (0.77) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL14027230 | 0.74 | EGFR (0.75) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL5569016 | 0.74 | EGFR (0.75) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL29894633 | 0.74 | ABCG2 (1.00) | EGFRABCG2DAPK3MAP4K4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640392-B1 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-01-07 | — | — | EP | disclosed |
| US-8815879-B2 | Substituted 4-(selenophen-2(or-3)-ylamino)pyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-10 | — | — | US | disclosed |
| EP-2640392-A2 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012066578-A2 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | RPS6, SULT1E1, SCLY | EGFR 319/4885ABCG2 607/4885DAPK3 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.